Cargando…

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer

ARAMIS is an international Phase III trial demonstrating the beneficial role of darolutamide, a novel anti-androgen that has been found to prolong metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. Darolutamide is a novel nonsteroidal androgen receptor antagonis...

Descripción completa

Detalles Bibliográficos
Autor principal: Aragon-Ching, Jeanny B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958984/
https://www.ncbi.nlm.nih.gov/pubmed/31249268
http://dx.doi.org/10.4103/aja.aja_52_19